A transformative collaboration between Royal Columbian Hospital Foundation (RCHF) and TD Bank Group is poised to redefine the landscape of cancer diagnostics at Royal Columbian Hospital (RCH). TD has committed $230,000 over two years to power a clinical validation and pilot study into molecular testing for lung cancer tumours. This marks a significant leap towards personalized cancer diagnosis and expanded patient treatment options.
The upcoming research initiative at RCH’s molecular cytogenetic laboratory will focus on Non-Small Cell Lung Cancer (NSCLC) and apply advanced next-generation sequencing technology. The project aims to drastically slash wait times for molecular testing of cancerous tumours, paving the way for more immediate and effective treatment protocols.
Jeff Norris, President and CEO of RCHF, enthusiastically endorsed the collaboration: “Teaming up with TD on this pivotal research endeavour is truly exhilarating. This initiative holds the potential to revolutionize cancer diagnostics at RCH, ensuring timely and precise treatment for patients facing a cancer diagnosis.”
Royal Columbian Hospital is a leader in advanced cancer treatments, diagnosing over 1,500 high-incidence cancers annually. The dedicated team at RCH goes beyond traditional diagnostics and performs predictive and prognostic biomarkers, ensuring personalized and effective treatment plans. RCH has the second-largest surgical pathology caseload volume in British Columbia, with over 70,000 diagnoses conducted yearly, reflecting its commitment to providing comprehensive and timely cancer care to its community.
In appreciation of TD’s philanthropic endeavours, RCHF will recognize TD on the prestigious Donor Wall of Thanks within the heart of Royal Columbian Hospital.
